A gene that has for decades been considered a tumor promoter, the PLK1 gene, can also perform the exact opposite function: halting the development of cancer. This finding is published in the journal Nature Communications. The role of PLK1 as a target for powerful drugs must now be reviewed since, depending on the type of tumor to be treated, it might be useful to inhibit it, or it might not. For the time being, the scientists have discovered that the expression of PLK1 in breast tumors can determine a different prognosis, depending on the tumor sub-type.
The PLK1 gene is essential for the division and proliferation of tumor cells. It has been known for years the overexpression of PLK1 is found in a large variety of tumor types, and on occasions this overexpression is associated with poor prognosis. For that reason, PLK1 has for decades been considered an oncogene, a gene that promotes the development of tumors. Plk1 is also a therapeutic target, since inhibiting its activity induces the death of cell tumors. In fact, there are Plk1 inhibitors already at advanced clinical stages.
However, curiously, the oncogenic nature of PLK1 has never been formally demonstrated. In other words, until now, no experiment has been designed to demonstrate that the overexpression of PLK1 does indeed contribute to tumor development.
That was the initial aim of researchers at the start of this joint research project. To this end, they modified the genome of a mouse so that it was possible to overexpress the PLK1 gene at will in these animals.
The first thing they noted was that these animals did not develop any more tumors than the normal mice. They then crossed their mice with others that expressed the oncogenes H-Ras or Her2 in their breast tissue, and hence they developed very aggressive breast tumors. They expected a much greater incidence of cancer, but the result was unexpected: by overexpressing PLK1 together with the oncogenes, the incidence of tumors was reduced drastically.
"That was when we realized that something important was happening," explained one of the lead researchers on this study. "And in effect we have shown that not only does PLK1 not act as an oncogene, but surprisingly it acts as a tumor suppressor".
Intrigued, the researchers consulted the breast cancer databases, in search of a link between the expression of PLK1 and patient prognosis. And they confirmed that "the expression of Plk1 can result in a very different type of prognosis depending on the tumour sub-type", said the author.
In Her2 positive tumors, the expression of PLK1 gives a better prognosis; however, in patients with positive tumors for the expression of the oestrogen receptor (ER+), it's the complete opposite. Not only does this paper describe the novel action of PLK1 as a tumor suppressor, it also identifies the molecular mechanism of how this suppression occurs. "We have seen that the overexpression of PLK1 increases the number of chromosomes in cells, because after they divide, cells cannot correctly segregate their chromosomes", said the lead researcher.
The fact that Plk1 acts as a tumor suppressor could call into question therapeutic strategies based on the inhibition of Plk1. However, the coordinator of the paper, trusts that the inhibition of Plk1 is still a valid and useful option.
"The fact that Plk1 is a tumor suppressor instead of an oncogene does not mean that Plk1 inhibitors will not be effective against cancer", said the author. "Many essential components in cell proliferation can be used as targets against cancer in spite of not having any oncogenic activity, owing to the addition of cancer cells to specific cell processes such as cell division".
The work of these researchers bestows value on the PLK1 gene as an oncological biomarker: "Understanding when PLK1 acts as an oncogene or as a tumor suppressor, and in which types of tumors this happens, is clinically extremely relevant when it comes to using this gene as a therapeutic biomarker", stresses the author.
https://www.cnio.es/es/publicaciones/descubren-un-nuevo-supresor-tumoral-que-hasta-ahora-era-considerado-un-oncogen
https://www.nature.com/articles/s41467-018-05429-5
Oncogene is now a tumor suppressor!
- 1,205 views
- Added
Edited
Latest News
Men with gene mutations are…
By newseditor
Posted 17 May
B cell oxidative phosphoryl…
By newseditor
Posted 17 May
Human brain gene therapy us…
By newseditor
Posted 16 May
Small-molecular mimic of a…
By newseditor
Posted 16 May
Centromere structure and ch…
By newseditor
Posted 16 May
Other Top Stories
Unfolding eye protein/s biogenesis
Read more
tBID can directly trigger cell death
Read more
Botox injections may reduce anxiety
Read more
Blood-clotting protein and gum disease
Read more
Genetic risk factors in sudden unexplained death in children (SUDC)
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
Obesity-induced blood-brain…
By newseditor
Posted 18 May
CRISPR/Cas9 model of prosta…
By newseditor
Posted 17 May
Modulation of host immunity…
By newseditor
Posted 17 May
Variability in cell divisio…
By newseditor
Posted 17 May
Biallelic BORCS8 variants c…
By newseditor
Posted 17 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar